COX-2 inhibitors: A story of greed, deception and death

Inflammopharmacology

Volumn 13, Issue 4, 2005, Pages 419-425

  Halpern, Georges M ^a,b  

^a HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

^b NONE   (United States)

Author keywords

Coxibs; Gastro intestinal bleeding; Greed; Lyprinol; NSAIDS; Risk

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ROFECOXIB;

ARTHRITIS; ARTICLE; BLOOD CLOTTING DISORDER; CARDIOTOXICITY; CARDIOVASCULAR RISK; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; NEPHROTOXICITY; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; STROKE;

ACETAMINOPHEN; ANALGESICS, NON-NARCOTIC; ANIMALS; CLINICAL TRIALS; CYCLOOXYGENASE 2 INHIBITORS; DRUG INDUSTRY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS;

EID: 27744504390     PISSN: 09254692     EISSN: None     Source Type: Journal    
DOI: 10.1163/156856005774415574     Document Type: Article

References (21)

1. Berenson, A. and Harris, G. (2005). Pfizer says 1999 trials revealed risks with Celebrex, NY Times, February 1.
2. Bertin, P., Keddah, K. and Jolivet-Landreau, I. (2004). Acetaminophen as symptomatic treatment of pain from osteoarthritis, Jt. Bone Spine 71, 266-274.
3. Bhattacharya, S. (2005). Up to 140,000 heart attacks linked to Vioxx, NewScientist.com, January 25.
4. Bradley, J. D., Brandt, K. D., Katz, B. P., et al. (1991). Comparison of an anti-inflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee, N. Engl. J. Med. 325, 87-91.
5. Butters, D. E. and Whitehouse, M. W. (2003). Treating inflammation: some (needless) difficulties for gaining acceptance of effective natural products and traditional medicines, Inflammopharmacology 11, 97-110.
6. Cho, S. H., Jung, Y. B., Seong, S. C., et al. (2003). Clinical efficacy and safety of Lyprinol, a patented extract from New Zealand green-lipped mussel (Perna canaliculus) in patients with osteoarthritis of the hip and knee: a multicenter 2-month clinical trial, Allerg. Immunol. 35, 212-216.
7. Dai, C., Stafford, R. S. and Alexander, G. C. (2005). National trends in cyclooxygenase-2 inhibitors since market release. Nonselective diffusion of a selectively cost-effective innovation, Arch. Intern. Med. 165, 171-177.
8. DeAngelo, N. A. and Gordin, V. (2004). Treatment of patients with arthritis-related pain, J. Am. Osteoarthr. Ass. 104, 2-5.
9. Gallagher, R. and Oransky, I. (2005). Who's minding the drug store?, Scientist 19, 6.
10. Gruenwald, J., Graubaum, H. J., Hansen, K., et al. (2004). Efficacy and tolerability of Lyprinol and high concentrations of EPA and DHA in inflammatory rheumatoid disorders, Adv. Ther. 21, 197-201.
11. Halpern, G. M. (2000). Anti-inflammatory effects of a stabilized lipid extract of Perna canaliculus (Lyprinol), Allerg. Immunol. 32, 272-278.
12. Halpern, G. M. (2001). Lyprinol. A Natural Solution for Arthritis and Other Inflammatory Disorders. Avery/Penguin Putnam, New York, NY.
13. Halpern, G. M. (2004). In: Ulcer Free! Nature's Safe and Effective Remedy for Ulcers, pp. 53-57. SquareOne Publishers, Garden City Park, NY.
14. Hillis, W. S. (2002). Areas of emerging interest in analgesia: cardiovascular complications, Am. J. Ther. 9, 259-269.
15. Jüni, P., Nartey, L., Reichenbach, S., et al. (2004). Risk of cardiovascular events and rofecoxib: cumulative meta-analysis, Lancet 364, 2021-2029.
16. Kovar, P. A., Allegrante, J. P., Mackenzie, C. R., et al. (1992). Supervised fitness walking in patients with osteoarthritis of the knee. A randomized, controlled trial, Ann. Intern. Med. 116, 529-534.
17. Kwan, D., Bartle, W. R. and Walker, S. E. (1999). The effect of acetaminophen on pharmacokinetics and pharmacodynamics of warfarin, J. Clin. Pharmacol. 39, 68-75.
18. Lau, C. S., Chiu, P. K. Y., Chu, E. M. Y., et al. (2004). Treatment of knee osteoarthritis with Lyprinol® lipid extract of the green-lipped mussel -a double-blind placebo-controlled study, Progr. Nutr. 6, 17-31.
19. Muller, P., Simon, B., Weise, D., et al. (1990). EndoscopiC studies on the gastric tolerance of paracetamol and acetylsalicylic acid. A placebo-controlled double-blind study in healthy volunteers, Arzneimittelforschung 40, 316-318.
20. Prescott, L. F. (2000). Paracetamol: past, present, and future, Am. J. Ther. 7, 143-147.
21. Swan, S. K., Rudy, D. W., Lasseter, K. C., et al. (2000). Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial, Ann. Intern. Med. 133, 1-9.